Julien Kirchgesner (J Kirchgesner)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 23

Top Topics

Randomized Controlled Trial

Ulcerative Colitis

Patients With Inflammatory Bowel Disease

Top Venues

Journal of Crohn's & colitis

Alimentary pharmacology & therapeutics

United European gastroenterology journal

This page only lists publications with an associated author ORCID identifier.

Publications

Massimo Claudio Fantini, Gionata Fiorino, Agostino Colli, David Laharie, Alessandro Armuzzi, Flavio Andrea Caprioli, Francisco Javier García-Alonso, Julien Kirchgesner, Fabio Salvatore Macaluso, Fernando Magro, Subrata Ghosh, null null
Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus. Journal of Crohn's & colitis 18 (8) (2024)
Massimo Claudio Fantini, Gionata Fiorino, Agostino Colli, David Laharie, Alessandro Armuzzi, Flavio Andrea Caprioli, Francisco Javier García-Alonso, Julien Kirchgesner, Fabio Salvatore Macaluso, Fernando Magro, Subrata Ghosh, null null
Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD European consensus. Journal of Crohn's & colitis (2024)
Saeed Shakibfar, Kristine Højgaard Allin, Tine Jess, Maria Antonietta Barbieri, Vera Battini, Eva Simoncic, Julien Kirchgesner, Trond Ulven, Maurizio Sessa
Drug Repurposing in Crohn's Disease Using Danish Real-World Data. Pragmatic and observational research 15 (2024)
Massimo Claudio Fantini, Gionata Fiorino, Agostino Colli, David Laharie, Alessandro Armuzzi, Flavio Andrea Caprioli, Francisco Javier García-Alonso, Julien Kirchgesner, Fabio Salvatore Macaluso, Fernando Magro, Subrata Ghosh, null null
Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus. Journal of Crohn's & colitis 18 (8) (2024)
Massimo Claudio Fantini, Gionata Fiorino, Agostino Colli, David Laharie, Alessandro Armuzzi, Flavio Andrea Caprioli, Francisco Javier García-Alonso, Julien Kirchgesner, Fabio Salvatore Macaluso, Fernando Magro, Subrata Ghosh, null null
Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD European consensus. Journal of Crohn's & colitis (2024)
Saeed Shakibfar, Kristine Højgaard Allin, Tine Jess, Maria Antonietta Barbieri, Vera Battini, Eva Simoncic, Julien Kirchgesner, Trond Ulven, Maurizio Sessa
Drug Repurposing in Crohn's Disease Using Danish Real-World Data. Pragmatic and observational research 15 (2024)
Julien Kirchgesner, Shirley V Wang, Sebastian G Schneeweiss
Strengthening Real-World Evidence on Question Not Answered by Randomized Trials: A Trial Calibration Approach. Pharmacoepidemiology and drug safety 33 (9) (2024)
Nathan Grellier, Julien Kirchgesner, M Uzzan, P McLellan, C Stefanescu, J H Lefevre, X Treton, Y Panis, Harry Sokol, L Beaugerie, null null, Philippe Seksik
Early ileal resection in Crohn's disease is not associated with severe long-term outcomes: The ERIC study. Alimentary pharmacology & therapeutics (2024)
Louis Calméjane, David Laharie, Julien Kirchgesner, Mathieu Uzzan
Review article: Updated management of acute severe ulcerative colitis: From steroids to novel medical strategies. United European gastroenterology journal (2023)
Julien Kirchgesner, Magali Svrcek
Letter: histologic disease activity and colorectal neoplasia risk-authors' reply. Alimentary pharmacology & therapeutics 57 (12) (2023)
Mathieu Uzzan, Maria Nachury, Alexandre Nuzzo, Aurélien Amiot, Bénédicte Caron, Alban Benezech, Anthony Buisson, Guillaume Bouguen, Catherine Le Berre, Catherine Reenaers, Guillaume Le Cosquer, Guillaume Savoye, Maeva Charkaoui, Mathias Vidon, Lucas Guillo, Mathurin Fumery, Laurent Peyrin-Biroulet, Julien Kirchgesner, Yoram Bouhnik, null null
Tofacitinib for patients with anti-TNF refractory ulcerative proctitis: a multicenter cohort study from the GETAID. Journal of Crohn's & colitis (2023)
Julien Kirchgesner, Laurent Beaugerie
Editorial: Pip pip to PIPs (post- inflammatory polyps) as a neoplasia risk factor in IBD? Authors' reply. Alimentary pharmacology & therapeutics 58 (3) (2023)
Nathan Grellier, Julien Kirchgesner
Inflammatory bowel diseases and eosinophilic oesophagitis: Two overlapping disorders? United European gastroenterology journal (2023)
Paul McLellan, Julien Kirchgesner
Perianal fistulizing Crohn's disease and overall risk of cancer: No red flag. United European gastroenterology journal (2023)
Thomas Wolf, Ayanna Lewis, Laurent Beaugerie, Magali Svrcek, Julien Kirchgesner, null null
Risk of colorectal neoplasia according to histologic disease activity in patients with inflammatory bowel disease and colonic post-inflammatory polyps. Alimentary pharmacology & therapeutics (2023)
Amélie Biron, Laurent Beaugerie, Olivier Chazouillères, Julien Kirchgesner
Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics 56 (5) (2022)
Paul McLellan, Julien Kirchgesner
Genital warts and inflammatory bowel diseases: Danish real-world evidence to assess patient-relevant outcomes. United European gastroenterology journal 10 (3) (2022)
Hannah Gordon, Livia Biancone, Gionata Fiorino, Konstantinos H Katsanos, Uri Kopylov, Eman Al Sulais, Jordan E Axelrad, Karthiha Balendran, Burisch J, Lissy de Ridder, Lauranne Derikx, Pierre Ellul, Thomas Greuter, Marietta Iacucci, Caroline Di Jiang, Christina Kapizioni, Konstantinos Karmiris, Julien Kirchgesner, David Laharie, Triana Lobatón Ortega, Tamás Molnár, Nurulamin M Noor, Rohit Rao, Simone Saibeni, Michael Scharl, Stephan R Vavricka, Timothy Raine
ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. Journal of Crohn's & colitis (2022)
Daniel J Ward, Mikael Andersson, Nynne Nyboe Andersen, Kristine Højgaard Allin, Laurent Beaugerie, Tine Jess, Julien Kirchgesner
Risk of acute arterial events associated with treatment of inflammatory bowel diseases: a nationwide Danish cohort study. Gut 71 (11) (2022)
Julien Kirchgesner, Rishi J Desai, Maria C Schneeweiss, Laurent Beaugerie, Sebastian Schneeweiss, Seoyoung C Kim
Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease. Gut 71 (9) (2022)
Chloé Michaudel, Camille Danne, Allison Agus, Aurélie Magniez, Anne Aucouturier, Madeleine Spatz, Antoine Lefevre, Julien Kirchgesner, Nathalie Rolhion, Yazhou Wang, Aonghus Lavelle, Chloé Galbert, Gregory Da Costa, Maxime Poirier, Alexia Lapière, Julien Planchais, Petr Nádvorník, Peter Illes, Cyriane Oeuvray, Laura Creusot, Marie-Laure Michel, Nicolas Benech, Anne Bourrier, Isabelle Nion-Larmurier, Cecilia Landman, Mathias L Richard, Patrick Emond, Philippe Seksik, Laurent Beaugerie, Rafael Rose Arguello, David Moulin, Sridhar Mani, Zdenek Dvorák, Luis G Bermúdez-Humarán, Philippe Langella, Harry Sokol
Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases. Gut (2022)
Julien Kirchgesner, Rishi J Desai, Maria C Schneeweiss, Laurent Beaugerie, Seoyoung C Kim, Sebastian G Schneeweiss
Emulation of a randomized controlled trial in ulcerative colitis with US and French claims data: Infliximab with thiopurines compared to infliximab monotherapy. Pharmacoepidemiology and drug safety (2021)
Julien Kirchgesner, Nynne Nyboe Andersen, Fabrice Carrat, Tine Jess, Laurent Beaugerie, null null
Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study. Gut 69 (5) (2019)